<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660268</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14.455</org_study_id>
    <nct_id>NCT02660268</nct_id>
  </id_info>
  <brief_title>Contribution of a Clinical Pathway for the Treatment of Hip Prosthesis Infections</brief_title>
  <acronym>OSCAR-PH</acronym>
  <official_title>Evaluation of the Implementation of a Clinical Pathway for Improving the Performance of Medical and Surgical Management of Hip Prosthesis Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine the contribution of a clinical pathway to improve the&#xD;
      effectiveness of medico-surgical management of hip prosthesis infections in terms of clinical&#xD;
      cure. The hypothesis raised is that the implementation of a clinical pathway would improve&#xD;
      the performance of the medical and surgical management of chronic infections of prosthetic&#xD;
      hip.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of surgical site infections following the orthopedic surgery is about 1%. The&#xD;
      number of prosthesis infections is estimated between 2000 and 2500 new cases a year in&#xD;
      France.&#xD;
&#xD;
      Multiple medical and surgical care strategies are possible depending on the acute or chronic&#xD;
      presentation, early or delayed antibiotic therapy; antibiotic therapy alone or associated&#xD;
      with joint lavage, or with a prosthesis change in one or in two stages; after a long or short&#xD;
      period of time, with or without fitting spacer. The practices are very heterogeneous for&#xD;
      chronic infections depending on the terrain on which infection occurs and modalities of&#xD;
      antibiotic therapy remain controversial. The treatment failure rate at 1 year is estimated at&#xD;
      20%.&#xD;
&#xD;
      The hypothesis raised is that the implementation of a clinical pathway would improve the&#xD;
      performance of the medical and surgical management of chronic infections of prosthetic hip.&#xD;
&#xD;
      Objectives: To determine the contribution of a clinical pathway to improve the effectiveness&#xD;
      of medico-surgical management of hip prosthesis infections in terms of clinical cure.&#xD;
&#xD;
      The secondary objectives are: To evaluate medical and surgical practices in diagnosis and&#xD;
      treatment of hip prosthesis infections; identify the success factors and therapeutic failure&#xD;
      of medical and surgical supported hip prosthesis infections in terms of clinical cure;&#xD;
      determining management of quality indicators.&#xD;
&#xD;
      Methods: The clinical path will be developed by a committee of experts from the national and&#xD;
      international recommendations, a review of the literature focused on the prosthesis&#xD;
      conservation strategies and audit practices at the University Hospital of Grenoble.&#xD;
&#xD;
      The clinical path will be evaluated by an interventional trial clustered with control group,&#xD;
      randomized, stepped wedge (inclusion staggered in time in 4 X 3 months) with an evaluation at&#xD;
      one year.&#xD;
&#xD;
      The study population will include all patients treated for hip prosthesis infection in&#xD;
      hospitals participating in the Alps, in a period of 16 months.&#xD;
&#xD;
      The primary endpoint will be the clinical cure at one year, defined as the absence of&#xD;
      clinical signs of infection, inflammatory syndrome (C-Reactive Protein &lt;10 mg / L), and&#xD;
      radiological signs of infection.&#xD;
&#xD;
      Analysis: The association between the primary endpoint and the introduction of a clinical&#xD;
      path will be quantified by the odds ratio estimated using a logistic regression model with&#xD;
      adjustment for baseline characteristics of patients and inclusion of non-independence of&#xD;
      observations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Anticipated">March 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure at 1 year of initial medical management, defined by the absence of the clinical signs of infection, the inflammatory syndrome (C- Reactive Protein &lt;10 mg / L) and the radiological signs of infection</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical cure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time duration between first clinical signs and diagnosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time duration between diagnosis and therapeutic management</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of antibiotic therapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conservation or removal of hip prosthesis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative length of hospital stay</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gap analysis between observed care and the clinical path</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional sequelae at one year</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at one year</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Hip Prosthesis Infection</condition>
  <arm_group>
    <arm_group_label>Clinical pathway</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group will be followed according to the clinical pathway</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will receive standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Pathway</intervention_name>
    <description>Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections</description>
    <arm_group_label>Clinical pathway</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject â‰¥ 18 years of age. Having a first episode of hip prosthesis infection defined&#xD;
             by an infectious disease physician on clinical , radiological and microbiological&#xD;
             criteria according the clinical practice guidelines of the French-Language Infectious&#xD;
             Diseases Society May 13, 2009&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Supported in one of the participating center (hospitals of Arc Alpin)&#xD;
&#xD;
          -  Covered by health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject &lt; 18 years of age&#xD;
&#xD;
          -  Inability to read and understand the participant's Information&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia PAVESE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia PAVESE, MD</last_name>
    <phone>+33 4 76 76 39 41</phone>
    <email>PPavese@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saber TOUATI, PhD</last_name>
    <phone>+33 4 76 76 58 05</phone>
    <email>stouati1@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Annecy Hospital</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Vitrat-Hincky, MD</last_name>
      <email>vvitrat@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Virginie Vitrat-Hincky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChambÃ©ry Hospital</name>
      <address>
        <city>ChambÃ©ry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Forestier</last_name>
      <email>emmanuel.forestier@ch-chambery.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Forestier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pavese, MD</last_name>
      <phone>+33 4 76 76 39 41</phone>
      <email>PPavese@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia Pavese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MylÃ¨ne Maillet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Saragaglia, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-paul Stahl, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Epaulard, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Pierre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Dentan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-paul Brion, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble.</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nastasia El-Zeenni, MD</last_name>
      <email>N.ELZEENNI@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Nastasia El-Zeenni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan FERRY, MD</last_name>
      <email>tristan.ferry@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Tristan FERRY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Nord-CHU Saint Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CÃ©line Cazorla, MD</last_name>
      <email>Celine.cazorla@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>CÃ©line Cazorla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Voiron Hospital</name>
      <address>
        <city>Voiron</city>
        <zip>38500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Guillaume, MD</last_name>
      <email>medecineb.guillaume@ch-voiron.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde Guillaume, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical pathway</keyword>
  <keyword>Infection</keyword>
  <keyword>Hip</keyword>
  <keyword>Prosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

